Last reviewed · How we verify
usage oral angiogenesis inhibitor — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
usage oral angiogenesis inhibitor (usage oral angiogenesis inhibitor) — Radboud University Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| usage oral angiogenesis inhibitor TARGET | usage oral angiogenesis inhibitor | Radboud University Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- usage oral angiogenesis inhibitor CI watch — RSS
- usage oral angiogenesis inhibitor CI watch — Atom
- usage oral angiogenesis inhibitor CI watch — JSON
- usage oral angiogenesis inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). usage oral angiogenesis inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/usage-oral-angiogenesis-inhibitor. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab